Literature DB >> 24715221

Hypoxia-induced miR-210 in epithelial ovarian cancer enhances cancer cell viability via promoting proliferation and inhibiting apoptosis.

Li'an Li1, Ke Huang1, Yanqin You1, Xiaoyu Fu1, Lingyun Hu1, Lei Song1, Yuanguang Meng1.   

Abstract

miR-210 is upregulated in a HIF-1α-dependent way in several types of cancers. In addition, upregulated miR-210 promotes cancer proliferation, via its anti-apoptotic effects. It is blind to the regulation of miR-210 under hypoxia conditions for ovarian cancer cells and to the effect of miR-210 on ovarian cancer growth. In the present study, we determined the expression of miR-210 in epithelial ovarian cancer specimens, and in ovarian cancer cell lines under hypoxia conditions, and determined in detail the effect of miR-210 overexpression on tumor cell proliferation, and the possible mechanisms of tumor growth by miR-210 regulation. It was shown that miR-210 expression is upregulated, in response to hypoxia conditions in epithelial ovarian cancer specimens as well as epithelial ovarian cancer cell lines, with an association to HIF-1α overexpression. Furthermore, upregulated miR-210 promoted tumor growth in vitro via targeting PTPN1 and inhibiting apoptosis. Therefore, our findings shed light on the mechanism of ovarian cancer adaptation to hypoxia.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24715221     DOI: 10.3892/ijo.2014.2368

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  25 in total

1.  miR-210, a modulator of hypoxia-induced epithelial-mesenchymal transition in ovarian cancer cell.

Authors:  Lu Ding; Le Zhao; Wei Chen; Ting Liu; Zhen Li; Xu Li
Journal:  Int J Clin Exp Med       Date:  2015-02-15

2.  HIF-2α, acting via miR-191, is involved in angiogenesis and metastasis of arsenite-transformed HBE cells.

Authors:  Wenchao Xu; Fei Luo; Baofei Sun; Hua Ye; Jun Li; Le Shi; Yi Liu; Xiaolin Lu; Bairu Wang; Qingling Wang; Qizhan Liu; Aihua Zhang
Journal:  Toxicol Res (Camb)       Date:  2015-11-06       Impact factor: 3.524

Review 3.  Reciprocal regulations between miRNAs and HIF-1α in human cancers.

Authors:  Wanli Yang; Jiaojiao Ma; Wei Zhou; Bo Cao; Xin Zhou; Hongwei Zhang; Qingchuan Zhao; Liu Hong; Daiming Fan
Journal:  Cell Mol Life Sci       Date:  2018-10-13       Impact factor: 9.261

4.  microRNA-126 suppresses PAK4 expression in ovarian cancer SKOV3 cells.

Authors:  Ping Luo; Jing Fei; Jianwei Zhou; Weijiang Zhang
Journal:  Oncol Lett       Date:  2015-03-03       Impact factor: 2.967

5.  The circulating microRNA-200 family in whole blood are potential biomarkers for high-grade serous epithelial ovarian cancer.

Authors:  Adam Pendlebury; Natalie J Hannan; Natalie Binder; Sally Beard; Monica Mcgauran; Peter Grant; Stephen Tong; Clare L Whitehead
Journal:  Biomed Rep       Date:  2017-01-25

Review 6.  Impact of Nutrition on Non-Coding RNA Epigenetics in Breast and Gynecological Cancer.

Authors:  Rosanna H E Krakowsky; Trygve O Tollefsbol
Journal:  Front Nutr       Date:  2015-05-27

Review 7.  MicroRNAs in brain metastases: potential role as diagnostics and therapeutics.

Authors:  Samer Alsidawi; Ehsan Malek; James J Driscoll
Journal:  Int J Mol Sci       Date:  2014-06-11       Impact factor: 5.923

8.  Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma.

Authors:  N-s Lai; D-g Wu; X-g Fang; Y-c Lin; S-s Chen; Z-b Li; S-s Xu
Journal:  Br J Cancer       Date:  2015-03-31       Impact factor: 7.640

9.  Serum miR-210 Contributes to Tumor Detection, Stage Prediction and Dynamic Surveillance in Patients with Bladder Cancer.

Authors:  Yongmei Yang; Ailin Qu; Jingkang Liu; Rui Wang; Yingjie Liu; Gang Li; Weili Duan; Qian Fang; Xiumei Jiang; Lili Wang; Guixi Zheng; Lutao Du; Xin Zhang; Chuanxin Wang
Journal:  PLoS One       Date:  2015-08-07       Impact factor: 3.240

10.  MiR-210 inhibits NF-κB signaling pathway by targeting DR6 in osteoarthritis.

Authors:  Dawei Zhang; Xiaorui Cao; Jun Li; Guangyue Zhao
Journal:  Sci Rep       Date:  2015-08-05       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.